menu

FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer

close
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
Restart
Resume
Read full article
Choose a format
Media formats available:
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Comments
  • Overview

    Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer.

    Released on December 21, 2017

Facebook Comments

Recommended
Details
Comments
  • Overview

    Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer.

    Released on December 21, 2017

Facebook Comments

Programs 6/19/21